Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thiopefilgrastim plus etoposide for autologous PBSC mobilization in lymphoma or multiple myeloma
ChiCTR2100053512Phase 4Recruiting
- Sponsor
- Union Hospital of Huazhong University of Science and Technology
- Start
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mecapegfilgrastim and etoposide in lymphoma and multiple myeloma (MM) (2 arms), sponsored by Union Hospital of Huazhong University of Science and Technology. Primary endpoint: Successful mobilization rate. Started Jul 2021; status: recruiting.
02
Drugs
mecapegfilgrastimetoposide
03
Conditions
lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2100053512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053512.